Jesús Zurdo

Jesús Zurdo is a biopharmaceutical scientist and innovation leader, and a cancer patient whose experience has reshaped how he thinks about drug development. Born in Madrid and based in the United Kingdom for some three decades, he trained as a molecular biologist and has spent his career in drug discovery, biologics manufacturing, and company creation, including innovation roles at Lonza. He was an early proponent of “developability” methods in biologic drug development and co-founded the biotech companies Zyentia and Zapaloid.

A little over three years ago, Zurdo was diagnosed with Philadelphia-positive acute lymphoblastic leukemia, an aggressive blood cancer. At diagnosis, 92 percent of his bone marrow had been taken over by immature cancerous cells. He went through intensive chemotherapy and a stem-cell transplant, made possible by an unrelated matched donor in Florida, and remains in remission.

Zurdo appeared on Open Door Salon to share that journey and what it taught him. He spoke candidly about the parts of cancer treatment that go undiscussed: the “brain fog” that lingers for years, the secondary conditions and latent risks a transplant leaves behind, and the survivor’s guilt he carried after a fellow patient with the same rare diagnosis did not survive.

His central message was for his own profession. As a scientist, he said, he once believed a “magic bullet” could cure; living as a patient taught him that what matters most is quality of life, that the language of “cure” is often untrue, and that drug developers who never listen to patients miss the interventions that would matter most. The work that remains, he argued, is to put scientists, clinicians, health economists, and patients around the same table.